Pfizer Inc. is undergoing a crucial transformation, highlighted by its recent $43 billion acquisition of Seagen to enhance its oncology pipeline, alongside the FDA's grant of Priority Review for a promising bladder cancer therapy. This shift comes as Pfizer grapples with declining revenues from COVID-19 vaccine sales and mixed analyst sentiments affecting stock performance. The company has pivoted towards the lucrative obesity drug market, aiming to stabilize its financial outlook amidst challenges like legal scrutiny over its vaccine approval processes and concerns over future revenue losses from patent expirations. The strategic focus on oncology and expanding its drug portfolio are central to Pfizer's efforts to navigate current market pressures and lead a recovery in growth.
Click a month on the chart to update the report below.
.svg&width=160)
%20-%20USA%20-%20UNOCHA.svg&width=160)
